Overview

Naltrexone Treatment of Alcohol Dependence

Status:
Completed
Trial end date:
2003-01-01
Target enrollment:
0
Participant gender:
All
Summary
The long-range goal of this ongoing research program is to find more effective treatments for alcohol dependence by combining medication with the appropriate psychosocial support. This proposal has three specific aims: (1) to compare the effectiveness of naltrexone (Revia) in three types of treatment settings; (2) to assess the effects of psychosocial support on medication compliance and treatment retention; and (3) to investigate the individual characteristics that may predict who is likely to benefit from additional psychosocial support versus simple medication management.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Treatments:
Naltrexone
Criteria
Inclusion Criteria:

- Meets criteria for current diagnosis of alcohol dependence.

- Subjects used more than 15 standard alcohol drinks (average)/week with at least 1 day
of 5 or more drinks in the past 30 days.

- Successful completion of medical detoxification.

- Lives within a commutable distance to the Treatment Research Center and agrees to
follow-up visits.

- Understands and signs the informed consent.

Exclusion Criteria:

- Current diagnosis of any substance dependence other than alcohol, nicotine, or
marijuana.

- Evidence of opiate use in the past 30 days.

- Current treatment with psychotropic medications, including disulfiram (Antabuse)
(excluding short-term use of benzodiazepines for detoxification).

- History of unstable or serious medical illness, including need for opioid analgesics.

- Severe physical or medical illnesses such as AIDS, active hepatitis, significant
hepatocellular injury as evidenced by elevated bilirubin levels, and current severe
psychiatric symptoms.

- Use of an investigation medication in the past 30 days.

- Female subjects who are pregnant, nursing, or not using reliable method of
contraception.